LONDON/COPENHAGEN, Dec 23 (Reuters) - Novo Nordisk secured U.S. regulatory approval for its weight-loss pill, giving the Danish drugmaker a shot at reclaiming ground lost ‌to rival Eli Lilly. Booming ...

Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market.

FILE PHOTO: The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, December 3, 2025. REUTERS/Tom Little/File Photo ...

A year after stopping taking weight loss drugs such as Ozempic and Wegovy, people regain, on average, 60% of their lost weight – but beyond this, their weight regain plateaus, with individuals ...

The Ozempic Effect originally premiered in 2025, but only landed on Netflix UK last Friday (February 27). It explores the use of GLP-1 drugs for weight management and how they are reshaping the ...

About 10 weeks after it was approved, the Wegovy pill is now estimated to be part of the daily regimen of about 400,000 Americans. And the field of weight-loss treatment is on the verge of even more ...

The Britalian Diet, created by Derbyshire based author and nutrition coach Francesca Bell, is resonating with readers who are fed up with restrictive diet culture. Based on her own 88 lb weight loss ...

LONDON/COPENHAGEN (Reuters) -Danish drugmaker Novo Nordisk is facing a major challenge to its blockbuster weight-loss drug Wegovy. Booming sales of Wegovy powered the firm to become Europe's most ...